MAPT and Alzheimer disease: Diagnostically, this implies that the information on ApoE4 carriership in AD is already “contained” in the pathological levels of Aβ42, t-Tau and p-Tau and thus, is not diagnostically relevant at the stage of MCI (Frölich et al. 2017).